Systematic Review and Pharmacological Considerations for Chloroquine and Its Analogs in the Treatment for COVID-19

作者：Hongwei Peng, Zhang-Ren Chen, Yunyun Wang, Simei Ren, Tiantian Xu, Xin Lai, Jinhua Wen, Meng-jun Zhao, Chuanfei Zeng, Lijuan Du, Yanmei Zhang, Li Cao, Jinfang Hu, Xiaohua Wei, Tao Hong · 发表于：Frontiers in Pharmacology · 年份：2020 · DOI：10.3389/fphar.2020.554172 · 被引用次数：9 · 研究领域：Drug-Induced Ocular Toxicity、Vitamin C and Antioxidants Research、COVID-19 Clinical Research Studies

analytical PBPK modeling, a further preliminary clinical trial has proved the efficacy and safety of CQ in China., and multiple clinical trials were registered and approved to investigate the activity of other analogs of CQ against COVID-19. We have listed all the clinical trials and made a meta-analysis of published data of hydroxychloroquine (HCQ). HCQ could increase the CT improvement and adverse reactions (ADRs) significantly though there was considerable heterogeneity among current researches. Actually, CQ and its analogs have unique pharmacokinetic characteristics, which would induce severe side effects in some circumstances. We have then summarized pharmacological considerations for these drugs so as to provide to the busy clinicians to avoid potential side effects when administered CQ or its analogs to COVID-19 patients, especially in the elderly, pediatrics, and pregnancies.